Nathaniel is a Partner at VC23 Investors and Vital Venture Capital. He has invested in 25 early-stage companies, mostly in the biotech, diagnostics and life science tools markets, including Twist Biosciences (now publicly traded), 10X Genomics, Ginkgo Bioworks, AxioMx, CD Diagnostics and many others. Nat has served on the boards of many portfolio companies. He has a 25 year successful track record of private investments, acquisitions and business management. The most recent example is HSA Bank, the largest specialty bank in the United States focused on health savings accounts. Nat has successful management experience in growth companies, including his role as CEO of HSA Bank.